Nanosonics share price slides lower on business update

Nanosonics shares are falling on Wednesday. Here's why…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Nanosonics share price is in the red on Wednesday
  • This follows the release of a business update
  • Nanosonics revealed that its direct sales model transition in North America is going well

The Nanosonics Ltd (ASX: NAN) share price is dropping on Wednesday.

In morning trade, the infection prevention company's shares are down 1.5% to $3.74.

young female doctor with digital tablet looking confused.

Image source: Getty Images

Why is the Nanosonics share price falling?

The weakness in the Nanosonics share price on Wednesday has been driven by the release of a business update.

This update was in relation to the company's direct sales model transition in North America which was announced in February.

According to the release, the direct sales model transition is progressing well with the transfer of GE customers currently in progress and a significant number of accounts already set up by Nanosonics.

The release notes that GE has been supporting Nanosonics with the transition by communicating with all of their trophon customers about the new arrangements being implemented for the ongoing provision of trophon products.

Furthermore, the relevant GE customer data has been supplied to Nanosonics and the company has communicated with all these customers to set up direct trading accounts. A significant number of these accounts are now in place. Management expects that the transition will be completed for the majority of customers by 30 June 2022.

Also supporting the transition will be a number of former GE High Level Disinfection team members that have joined Nanosonics. These include the previous Head of the GE High Level Disinfection team, a GE operations lead who was responsible for the supply and logistics of trophon products to all GE customers, and a number of sales managers.

Trading update

During the third quarter, Nanosonics' global installed base grew to 28,900. This is up a modest 2.6% from 28,160 units at the end of December. It could be this subdued growth that is weighing on the Nanosonics share price today.

Nevertheless, management revealed that it expects its full-year revenue to be in line with current market consensus estimates.

Furthermore, Nanosonics' Chief Executive Officer and President, Michael Kavanagh, believes the transition will benefit the company. He commented:

The continued transition to a more direct sales channel model in North America brings many benefits to Nanosonics and its customers. Our North American team can now manage the overall growth strategy associated with new installed base, upgrade adoption and consumables usage. This deeper relationship with our North American customers together with our corresponding infrastructure expansion also supports planned product expansion beyond trophon.

We are very pleased with the ongoing progress being made with the transition to the updated sales model. Our North American team and the GE healthcare ultrasound team continue to collaborate well ensuring the current and future infection prevention needs of all customers and their patients are fully met.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics Limited. The Motley Fool Australia has positions in and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Up 15% in a week, is it too late to buy rebounding CSL shares?

CSL shares trade on roughly 13 times forecast FY26 earnings and offer a good dividend yield.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Broker Notes

Down 60%, are Cochlear shares now a bargain buy?

A leading analyst provides his outlook for Cochlear’s beaten-down shares.

Read more »

Young woman thinking with laptop open.
Healthcare Shares

Why are Sigma Healthcare shares in the spotlight this week?

Is the latest sell-off overdone?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Is it time to get greedy with Pro Medicus shares?

The company was swept up in the huge sector-wide downturn in late 2025 and early 2026 as investors turned their…

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development.
Healthcare Shares

Prediction: I think Telix shares could double in value in 2026. Here's why

The biopharmaceutical company's shares dipped to a three-year low in February, but have now rebounded strongly.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

How much does UBS think CSL will bounce back?

If the worst is over, what's the upside for the shares?

Read more »

Woman with long hair smiles for the camera.
Healthcare Shares

Why I'd buy CSL shares while sentiment is weak

The market no longer treats this ASX healthcare giant as flawless, and that may make the investment case more interesting.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Is this exciting healthcare stock a buy, hold or sell after rocketing 16% yesterday?

Can this soaring stock keep rising?

Read more »